Update on reintroduction of epoetin in a patient with pure red call aplasia

Nephrology Dialysis Transplantation

Volumn 23, Issue 10, 2008, Pages 3365-

  Campbell, Neil ^a   Krishnakumar, Sarietha ^a   Matijevic, Ante ^a   Almond, Mike ^a  

^a BASILDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LETTER; MALE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANEMIA; CYCLOSPORINE; EPOETIN ALFA; HEMATINICS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; MALE; RED-CELL APLASIA, PURE;

EID: 52449114818     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn328     Document Type: Letter

References (3)

1. MacDougall IC. Epoetin-induced pure red cell aplasia: diagnosis and treatment. Curr Opin Nephrol Hypertens 2007; 16: 585-588
2. Andrade J, Taylor PA, Love JM et al. Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisolone. Nephrol Dial Transplant 2005; 20: 2548-2551
3. Summers SA, Matijevic A, Almond MK. Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia. Nephrol Dial Transplant 2004; 19: 2137-2139